MedTrace Logo

Effectiveness of a Person-centred Prescription Model at the End of Life

NCT05454644 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2022-07-12

No results posted yet for this study

Summary

This study's main objective is to investigate whether the application of an adapted person-centred prescription model during a hospital stay would reduce the use of inappropriate or futile regular medications in older people at the end of life, improving their clinical/health statuses and reducing the expense associated with pharmacological treatment. We hypothesised that applying this modified method could optimise pharmacotherapeutic indicators and the expense associated with the pharmacological treatment of hospitalised patients

Conditions

  • End-Of-Life
  • Inappropriate Prescribing
  • Deprescriptions
  • Palliative Medicine
  • Geriatrics

Interventions

OTHER

Person-Centred Prescription Model

Step 1: Identify patients with advanced chronic condition and limited life expectancy. Step 2: Interview with patients or closes caregiver. Step 3: Medication Review The clinical pharmacist conduct a structured medication review based on the medication appropriateness index (MAI): * Indication/effectiveness: Product information, STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with limited life expectancy) criteria and Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. * Dosage adjustment: Product Information and Lexi-Comp's Geriatric Dosage Handbook. * Correct and practical directions: Medication Regimen Complexity Index (MRCI). * Drug-drug interactions: Bot Plus/Beers Criteria and drug burden index (DBI), which measures dose-dependent anticholinergic and sedative loads. * Drug-disease interactions: Beers Criteria. * Duplication, duration and cost-effectiveness: Product information. Step 4: Treatment Plan

Sponsors & Collaborators

  • University of the Basque Country (UPV/EHU)

    collaborator OTHER

  • Universidad de León

    collaborator OTHER

  • Matia Foundation

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-15
Primary Completion
2020-02-28
Completion
2021-02-28

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05454644 on ClinicalTrials.gov